Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QUTENZA repeat-application safety study in painful diabetic peripheral neuropathy
NL-OMON39911Phase 3Active, not recruiting
- Sponsor
- Astellas Pharma
- Start
- Jun 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of capsaicin in diabetic polyneuropathy (DPN) (3 arms), sponsored by Astellas Pharma. Primary endpoint: Primary safety endpoint. Started Jun 2012; status: active, not recruiting.
02
Drugs
capsaicin
03
Conditions
diabetic polyneuropathy (DPN)
Beyond the preview
Go deeper on NL-OMON39911.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON39911.